Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-09-02 Transaction in Own Shar…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is a formal declaration by Sanofi regarding the repurchase of its own shares (transactions sur actions propres) over a specific period (August 25, 2025, to August 29, 2025). It includes both an aggregated summary table and a detailed transaction-by-transaction log, which is standard for 'Transaction in Own Shares' (POS) filings under market abuse regulations (MAR).
2025-09-02 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the purchase of its own shares (share buyback) over a specific period (August 25 to August 29, 2025). It includes detailed tables of daily volumes, weighted average prices, and individual transaction logs. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-09-02 English
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi announcing the FDA approval of a new drug, 'Wayrilz'. It details the clinical trial results (LUNA 3 study), the drug's mechanism, and regulatory status. It does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication announcement (RPA) as it provides substantive news content. As a general corporate regulatory announcement regarding product development and regulatory approval, it falls under the 'Regulatory Filings' (RNS) category.
2025-08-29 English
Communiqué de presse : Wayrilz de Sanofi est approuvé aux États-Unis comme premier inhibiteur de BTK pour la thrombocytopénie immune
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing the FDA approval of a new drug, 'Wayrilz'. It details the clinical trial results (LUNA 3), the drug's mechanism, and its regulatory status. This type of corporate communication regarding product development and regulatory milestones is classified as a general regulatory announcement or corporate news, which falls under the 'RNS' (Regulatory Filings) category in the provided schema.
2025-08-29 French
6-K
Foreign Filer Report
2025-08-29 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the repurchase of its own shares over a specific period (18 August 2025 to 22 August 2025). It includes detailed tables of daily transaction volumes, weighted average prices, and individual trade logs. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-08-25 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.